// App-Quantinova.ai

1943 : Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Researchers

Presenter

  • Scott R. Daigle

Principal Investigators

  • Courtney D. DiNardo

  • Anthony S. Stein

  • Eytan M. Stein

  • Amir T. Fathi

  • Olga Frankfurt

  • Andre C. Schuh

  • Hartmut Dhner

  • Giovanni Martinelli

  • Prapti Patel

  • Emmanuel Raffoux

  • Peter Tan

  • Amer M. Zeidan

  • Stephane De Botton

  • Richard M. Stone

  • Mark Frattini

  • Aleksandra Franovic

  • Emily Xu

  • Thomas Winkler

  • Bin Wu

  • Paresh Vyas

Medical Centers

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

  • City of Hope National Medical Center, Duarte, CA

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Ulm, Ulm, Germany

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Division of Hematology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France, France

  • Department of Haematology Cell and Tissue Therapies, Royal Perth Hospital, Perth, Australia

  • Yale University-Yale Cancer Center, New Haven, CT

  • Institut Gustave-Roussy, Villejuif, France

  • Dana-Farber/Partners CancerCare, Boston, MA

  • Bristol-Myers Squibb, New York City, NY

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • University of Oxford, Oxford, United Kingdom

Locations

  • United States

  • Canada

  • Germany

  • Italy

  • France

  • Australia

  • United Kingdom

Companies

  • Agios Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02677922

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved